Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Ann Oncol. 2018 Nov 1;29(11):2269. doi: 10.1093/annonc/mdx807.
No abstract available

Publication types

  • Published Erratum